ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0745

Tocilizumab in Monotherapy vs. Combined in Aortitis Associated with Giant Cell Arteritis. Multicenter Open-label Study of 196 Patients
Abstract Number: 0746

Single-cell RNA-Seq Analysis Reveals Distinct Compositional Characterizations and Transcriptomic Profiles of Macrophages in Takayasu’s Arteritis
Abstract Number: 0747

Clofutriben to Improve the Benefit-Risk Profile of Prednisolone in Patients with Polymyalgia Rheumatica
Abstract Number: 0748

Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica
Abstract Number: 0749

Age at Disease Onset Influences the Clinical Phenotype and Outcome of Patients with Takayasu Arteritis: Results from a Monocentric Cohort of 167 Patients
Abstract Number: 0750

Corticosteroid Withdrawal Using Tocilizumab and Its Association with Autoantibody Profile in Takayasu Arteritis: A Multicenter, Single-arm, Prospective Study
Abstract Number: 0751

Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry
Abstract Number: 0752

Non-classical Organ Involvement in Giant Cell Arteritis
Abstract Number: 0753

Treatment and Evolution in 134 Patients with Aortitis and Periaortitis. Experience of a Single Referral Centre
Abstract Number: 0754

Clinical Characterization of Aortitis and Periaortitis in a Cohort of 134 Patients from a Single Universitary Center. A Model-based Cluster Analysis
Abstract Number: 0755

Characteristics Associated with Long-Term Glucocorticoids Use in Patients with New Onset Polymyalgia Rheumatica
Abstract Number: 0756

Effectiveness and Safety of Tocilizumab in the Treatment of Polymyalgia Rheumatica: A Meta-Analysis
Abstract Number: 0757

Regulation of Macrophage Differentiation by Serum Adiponectin: A Novel Mechanism to Increase Alternatively Activated Macrophages During the Remission Phase of Giant Cell Arteritis
Abstract Number: 0758

Difficult to Treat Takayasu Arteritis: Comparative Efficacy of Colchicine and Tofacitinib
Abstract Number: 0759

Macrophage-Lineage Cells in Giant Cell Arteritis Express MMP12, Phagocytosis and Osteoclast-associated Molecules That May Contribute to Destruction of the Tunica Media

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].